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ABSTRACT A competition radioimmunoassay was devel-
oped, utilizing a murine monoclonal antibody to human pan-
creatic adenocarcinoma cells. Immunoblotting of a standard
antigen preparation from either serum or ascites fluid after
electrophoresis in 1% agarose showed that the specific DU-
PAN-2 activity resided in two major high molecular weight
bands. DU-PAN-2 antigen levels were expressed as arbitrary
units based on a standard partially purified antigen prepa-
ration. The inhibition curve with standard antigen was re-
producible (SD < 10%) and essentially linear from 25 to 200
units/ml. The mean DU-PAN-2 antigen concentration for the
sera from 126 normal individuals was 81 units/mi. Sera from
pediatric patients with malignancy had a mean of 127 units/ml,
while nasopharyngeal, stage III melanoma, and ovarian car-
cinoma patients had means of 89, 92, and 119 units/mi,
respectively. All values in normal subjects as well as the
melanoma, nasoplaryngeal, ovarian, and pediatric cancer
patients were Wiss than 400 units/mi. Intermediate antigen
levels were detected in patients with alimentary tract malig-
nancies. Eight of 20 gastric cancer and 8 of 76 colorectal
carcinoma patients and 3 patients with benign or nonmalig
nant gastrointestinal tract disease had DU-PAN-2 values ex-
ceeding 400 units/ml. Ascites fluids from 6/6 and pancreatic
juice from 2/2 pancreatic cancer patients had values greater
than 750 units/ml. Serum from 68% of the 89 pancreatic
cancer patients tested had DU-PAN-2 antigen levels greater
than 400 units/ml. The mean serum value in this patient
population was 4888 units/mi.
Carcinoma of the pancreas is the fifth leading cause of cancer
death in the United States (1) and the incidence of the disease
appears to be rising (2). Once discovered, the disease is
nearly uniformly fatal. The high mortality relates to the
inability to make the diagnosis early, limited successful
therapy, and poor capacity for recognizing recurrent or pro-
gressive disease. A reliable protocol for detecting and moni-
toring pancreatic cancer could enhance treatment of the
disease. We have produced a monoclonal antibody to pan-
creatic adenocarcinoma that might provide such a tool.
We have previously reported on the production and partial
serological characterization of five monoclonal antibodies
elicited to the human pancreatic adenocarcinoma cell line
HPAF (3). One of these monoclonal antibodies, DU-PAN-2,
detects an antigen present on some cells of fetal pancreas and
on ductal epithelial cells of normal adult pancreas, as well as
on adenocarcinoma cells of pancreatic and nonpancreatic
origin (3, 4). Recent studies of the tissue distribution of this
antigen indicated that the antigen is probably a secretory cell
product. Although DU-PAN-2 antigen is not a tumor-specific
marker, there is a marked difference in the level of expres-
sion of the antigen on neoplastic tissues compared to analo-
gous nonneoplastic structures (4). Preliminary studies on the
molecular properties of the DU-PAN-2 antigen suggest that
the epitope is sensitive to neuraminidase and is expressed on
a large, heavily glycosylated molecule (ref. 5 and unpub-
lished data). In this report, we describe the electrophoretic
properties of the DU-PAN-2 antigen and its identification by
immunoblotting. A competition radioimmunoassay (RIA) for
the antigen was also developed, using the DU-PAN-2 IgM
monoclonal antibody. This report describes the use of this
competition RIA to detect and monitor the levels of DU-
PAN-2 antigen in serum and ascites of patients with various
malignant and nonmalignant diseases.
MATERIALS AND METHODS
DU-PAN-2 Antigen. The DU-PAN-2 antigen used as target
antigen for the RIA and as a standard antigen for the inhi-
bition curves was prepared from ascites of a patient with
pancreatic adenocarcinoma. An immunoaffinity column
could not be used for antigen purification because the DU-
PAN-2 IgM antibody shows poor antigen binding when cou-
pled to an insoluble matrix. Therefore, the antigen was
partially purified by other techniques. A 50-75% saturated
ammonium sulfate fraction of the ascitic fluid contained
>95% of the DU-PAN-2 antigen. Since human serum albu-
min in the ascites fluid precipitated with DU-PAN-2 antigen
in the 50-75% saturated ammonium sulfate fraction, material
from that fraction was dialyzed against 20 mM sodium phos-
phate, pH 7.1, and chromatographed on a Cibacron blue
F3G-A-Sepharose CL-6B column to remove albumin. More
than 90% of the DU-PAN-2 antigen was eluted within one
bed volume, while 90% or more of the albumin was removed.
The antigen preparation recovered from the Cibacron blue
F3G-A-Sepharose CL-6B column was then treated with 1.0
M perchloric acid for 15 min in an ice bath, centrifuged at
15,000 x g for 5 min, decanted, neutralized, and dialyzed
overnight against phosphate-buffered saline.
For electrophoretic and immunoblot analysis, DU-PAN-2
antigen was also purified by cesium bromide density gradient
centrifugation (6) from serum of pancreatic cancer patient.
This serum had 1000 units of D -PAN-2 antigen per ml by
competition RIA. The serum was dialyzed against deionized
water. Cesium bromide (42%, wt/wt) was then added to
achieve a loading density of 1.43 g/cm3. The samples were
centrifuged for 72 hr at 10'C and 30,000 rpm in a Beckman
SW 41 Ti rotor. The high-density fractions were collected,
dialyzed against water, and lyophilized. A different approach
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was taken to purify the antigen from serum due to the high
concentration of other serum proteins, which interfered with
the standard ascites protocol.
Competition RIA. Flexible polyvinyl chloride 96-well plates
(Dynatech, Alexandria, VA) were prepared for antigen coat-
ing by adding 40 Al of 50 ,g/ml poly(L-lysine) (Sigma, P1274)
per well. After a 30-min incubation at room temperature, the
plates were washed once with phosphate-buffered saline and
were incubated overnight at 40C with 50 Al of phosphate-
buffered saline containing 1000 units (defined below) of par-
tially purified DU-PAN-2 antigen (see above). Meanwhile, 50
,ul of a test sample or control material was incubated over-
night at 4TC with 50 ,l of DU-PAN-2 IgM antibody from
tissue culture supernatant (0.2-0.3 Ag of IgM per ml) in RIA
buffer (1% bovine serum albumin/1% normal goat serum in
phosphate-buffered saline). After the overnight incubation,
the antigen-coated plates were washed once with phosphate-
buffered saline and incubated 30 min at room temperature
with 50 ,ul of RIA buffer. RIA buffer was then removed from
the wells and 40 1Al of the test sample/DU-PAN-2 antibody
mixture was added to duplicate wells. The plates were in-
cubated for 1 hr at room temperature and washed four times
with phosphate-buffered saline. RIA buffer (100 1.l) contain-
ing approximately 8 x 105 cpm of 125I-labeled F(ab')2 frag-
ments of goat antiserum to mouse Ig was then added and the
mixture was incubated for 2 hr at room temperature. The
plates were then washed seven times in phosphate-buffered
saline and dried, and radioactivities in individual wells were
determined in a gamma spectrometer. The conditions and
materials described above were judged to be optimal for DU-
PAN-2 antigen detection by varying the concentrations of
the first and second antibody and the times and temperatures
of the incubations. The overnight incubation of the test
sample and DU-PAN-2 antibody at 4°C could be changed to
2 hr at room temperature. However, since the antigen coat-
ing of the plates required an overnight incubation we pre-
ferred to use the overnight incubation at 4°C for the antibody
inhibition phase as well. DU-PAN monoclonal antibodies 1,
3, 4, and 5 (3) failed to show significant binding with the DU-
PAN-2 antigen in this RIA.
Agarose Gel Electrophoresis and Immunoblotting. Lyophil-
ized DU-PAN-2 antigen from both serum and ascites was
dissolved in sodium dodecyl sulfate/polyacrylamide gel elec-
trophoresis sample buffer (7) without 2-mercaptoethanol and
then subjected to horizontal slab gel electrophoresis in 1.0%
agarose in Tris/boric acid/EDTA buffer containing 0.1%
sodium dodecyl sulfate, at 100 V, for 4 hr (8). Transfer to
nitrocellulose paper was performed by electroblotting at 30
V, overnight in the cold. The sheet was then incubated with
5% bovine serum albumin at 40°C followed by DU-PAN-2
antibody or a control antibody at room temperature for 1 hr
with continuous rocking. After washing, the paper was in-
cubated for 1 hr with rabbit antibody to mouse IgM, followed
by 1-hr incubation with 125I-labeled staphyloccal protein A at
106 cpm/ml. The blots were again extensively washed, blot-
ted dry, and exposed to Kodak X AR-5 x-ray film with an
intensifying screen at -70°C for 1 hr.
Clinical Samples. Serum, plasma, and ascites samples were
obtained from normal volunteers and patients with malignant
and nonmalignant disease. Some of the samples were ob-
tained directly from the patient and then tested before freez-
ing, while other samples, often from the serum banks of
collaborating investigators, were tested after freezing. The
samples from pediatric patients with lymphomas or solid
tumors were obtained from Dr. Barry Dowell, Texas Chil-
drens Hospital, Houston; the sera from nasopharyngeal car-
cinoma patients were from Dr. T. C. Lynn, National Taiwan
University Hospital, Taipei; and the sera from ovarian can-
cer patients was obtained from Dr. Stanley Gall, Department
of Obstetrics-Gynecology, Duke University Medical Center,
Durham, NC.
RESULTS
Immunoblot of DU-PAN-2 Antigen. We have analyzed the
binding reactivity of DU-PAN-2 antibody with soluble an-
tigen preparations from ascitic fluid and serum of pancreatic
adenocarcinoma patients. Both preparations were partially
purified, subjected to electrophoresis in 1% agarose, and
immunoblotted as described in Materials and Methods.
The DU-PAN-2 antibody gave similar patterns of reactiv-
ity with the antigen preparations from both serum (Fig. 1,
lane B) and ascites fluid (Fig. 1, lane C). Two prominent
bands were seen with each antigen and the apparently higher
molecular weight bands from both sources migrated to the
same positions on the gels. The lower molecular weight band
from serum migrated slower and was less intense than that
from ascites. An IgM monoclonal antibody to a human
myeloid cell antigen failed to detect bands in these regions
(Fig. 1, lane A) in either preparation.
RIA. Rather than express the results as percent inhibition
and titer, we express the quantity of DU-PAN-2 antigen in a
sample as arbitrary units/ml based on reference to the par-
tially purified standard antigen sample (see Materials and
Methods). The amount of DU-PAN-2 antigen in 20 1l of a
1:500 dilution of the standard antigen preparation was das-
ignated as 100 units/ml. As shown in Fig. 2, a semilogarith-
mic plot of the percent inhibition vs. DU-PAN-2 antigen
concentration is essentially linear over the range of 20-70%
inhibition and could therefore be used as a standard curve for
calculating antigen concentration in an unknown sample.
The standard deviations ranged from 9.8% at 25 units/ml to
6.5% at 200 units/ml and were calculated from the mean of
13-21 determinations for each point. Each of these deter-
minations was done on different testing dates over a 2- to 3-
month period. Thus, the between-assay variability for the
standard antigen preparation was 10% or less. Purified car-
cinoembryonic antigen, ABO, and Lewis blood group an-
tigens gave less than 5% inhibition in the RIA. Body fluid
samples being tested for DU-PAN-2 antigen were then ti-
tered by 1:1 dilutions and units/ml were calculated from the
dilution giving between 30% and 70% inhibition.
Partially purified DU-PAN-2 antigen was stable at 100'C
for more than 15 min and there has been no loss ofDU-PAN-
2 antigen activity in the standard antigen preparation stored
at - 20'C for over 1 year. Sera from patients with high levels





FIG. 1. Analysis of DU-PAN-2 antigens by 1% agarose gel elec-
trophoresis and immunoblotting. Lane A, immunoblot of either an-
tigen with DU-HL60-3, an IgM antibody to a myeloid cell antigen.
DU-PAN-2 antibody was used in immunoblots of serum antigen
(lane B) and ascites antigen (lane C). Thyroglobulin (Mr, 669,000),
ferritin (Mr, 440,000), and catalase (Mr, 232,000) were used as mo-
lecular weight standards.
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FIG. 2. DU-PAN-2 standard antigen titration. Partially purified
DU-PAN-2 antigen was titrated in the competition RIA and the val-
ues are plotted as arbitrary units vs. percent inhibition. Bars indi-
cate the standard deviation of at least 13 different determinations
over a 3-month period.
shown any marked changes in DU-PAN-2 units after storage
at -20TC for 6 months. Patients' sera stored longer than 2
years at -20'C still had high levels of DU-PAN-2 antigen
when tested.
Detection of DU-PAN-2 Antigen in Ascites and Cyst Fluids.
Ascites fluid from the patient from whom the HPAF cell line
was derived was used as the source of the standard antigen.
The untreated and perchloric acid-extracted ascites fluid
from this patient contained more than 50,000 units/ml,
whereas ascites fluid from a patient with chronic renal failure
had less than 10 units/ml. Ascites or cyst fluid samples were
not tested at less than a 1:4 dilution. All of the ascites fluids
from patients with pancreatic adenocarcinoma had 750 or
more units/ml, whereas ascites fluid from one patient with
chronic renal failure and three patients with leukemia or
lymphoma had <10 units/ml (Table 1). Patients with other
types of solid tumors gave intermediate levels ranging from
<100 units/ml to 1000 units/ml. Fluid aspirated from pseu-
docysts from two patients with pancreatitis had <50 units/ml,
whereas fluid from a patient with a mucinous cyst adeno-
carcinoma of the pancreas had >100,000 units/ml. Fluid
from the pancreatic duct of two pancreatic adenocarcinoma
patients was taken at the time of surgical resection and was
found to have 2400 and 5200 units/ml. Pancreatic duct fluid
from a patient with a nongastrointestinal tract malignancy
had only 83 DU-PAN-2 units/ml.
Detection of DU-PAN-2 Antigen in Serum. Sera from nor-
mal volunteers, from patients with a variety of malignant
diseases, and from patients with pancreatitis were titered in
the competition RIA; the DU-PAN-2 units/ml were calcu-
lated and expressed in a dot chart (Fig. 3). Data on the sera
from patients with pancreatitis and pancreatic adenocarci-
noma were plotted irrespective of their clinical status at the
time the serum sample was obtained. The patients with other
malignancies had progressive disease at the time the sample
was taken but some were receiving therapy. The mean DU-
PAN-2 concentration for the sera from 126 normal individu-
als was 81 units/ml. Sera from pediatric patients with solid
tumors or lymphomas had a mean of 127 units/ml, while
nasopharyngeal carcinoma, stage III melanoma, and ovarian
cancer patients with a heavy tumor burden had means of 89,
92, and 119 units/ml, respectively. All values in normal
subjects as well as the melanoma and pediatric cancer pa-
tients were less than 300 units/ml and only infrequently were
values above 200 units/ml in these groups. Of the 55 ovarian
cancer patients tested in this study, none had values >400
Table 1. Detection of DU-PAN-2 antigen in ascites and cyst
fluids from patients with malignant and nonmalignant disease









































































units/ml. Intermediate antigen levels were detected in pa-
tients with alimentary tract malignancies. Eight of 20 gastric
cancer and 8 of 76 colorectal carcinoma patients had values
greater than 400 units/ml. Only 3 of 48 patients with benign
gastrointestinal tract disease, including pancreatitis, had val-
ues exceeding 400 units/ml. Of 89 tested patients with pan-
creatic carcinoma, 77% had DU-PAN-2 antigen levels greater
than 300 and 68% had values greater than 400 units/ml. The
mean DU-PAN-2 value in this patient population was 4888
units/ml. Serum from 14 of the pancreatic cancer patients
had levels between 10,000 and 100,000 units/ml (shown as
>7000 in Fig. 3).
Some of the pancreatic adenocarcinoma patients reported
in Fig. 3 to have low DU-PAN-2 antigen values were receiv-
ing therapy and were classified as having stable or minimal
diseases. We were, therefore, interested in doing serum
antigen determinations on different dates to investigate pos-
sible correlations between antigen levels and disease status.
Serial serum samples from most pancreatic cancer patients
were not readily available for this type of retrospective
study. Samples from two patients were available, however,
and data from these patients are indicative of the problems
and questions that need to be addressed by future prospec-
tive studies (Table 2). Serum DU-PAN-2 antigen levels in
patient A were mildly elevated (380 units/ml) when the
patient was first seen for obstructive jaundice. The antigen
levels declined after a bypass operation. The patient's bil-
irubin was also elevated initially due to the common bile duct
obstruction. When the hepatic duct was later obstructed,
both the DU-PAN-2 antigen and bilirubin levels were at their
highest, 1400 units/ml and 18.3 mg/dl, respectively. When
the hepatic duct obstruction was relieved, liver function
improved and the DU-PAN-2 antigen concentration became
normal. Throughout this period, patient A was not receiving
therapy and her tumor burden remained stable as well as
could be clinically documented.
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FIG. 3. DU-PAN-2 antigen levels of sera from normal volunteers and patients with pancreatitis or cancer. Each dot represents the mean
of triplicate determinations from a single testing date. Samples from normal donors having 100 units/ml or less were too numerous to depict
as dots and are shown as a solid rectangle. CA, carcinoma; NPC, nasopharyngeal carcinoma. The benign GI category includes pancreatitis
and benign or nonmalignant gastrointestinal tract disease.
Patient B (Table 2) showed a drop in DU-PAN-2 antigen
from 992 to 190 units/ml within 3 days of resection of his
primary pancreatic tumor. The patient remained clinically
stable for over 1 year with normal DU-PAN-2 levels and then
was found to have recurrent and progressive disease with
Table 2. Serial data on pancreatic cancer patients
Sample Bili- DU-PAN-2,
date Clinical summary AP rubin units/ml
Patient A
10/06/82 Obstructive jaundice due 199 8.6 380
to tumor
11/16/82 No clinical jaundice ND ND 126
12/23/82 Extreme clinical jaundice 260 3.6 ND
1/25/83 Deeply jaundiced; ob- ND 18.3 1400
structed hepatic duct
3/03/83 Subclinical jaundice 164 2.7 ND
4/27/83 No clinical jaundice; ob- ND ND 166
structed duct relieved
Patient B
12/10/81 Preoperative sample; ex- 135 2.4 992
tensive primary dis-
ease; no evidence of
metastases
12/14/81 Three days postoperative 103 1.0 190
1/04/82 Stable clinically; no evi- 98 0.4 176
dence of disease
6/18/82 Progressive disease 576 2.2 992
7/12/82 Progressive disease 295 1.0 1216
AP, alkaline phosphatase; ND, not done. Alkaline phosphatase is
expressed as international units/ml; bilirubin is mg/dl.
elevated DU-PAN-2 antigen in June 1982. The patient ex-
pired in July 1982, when DU-PAN-2 antigen was 1216
units/ml. There was a poor correlation in this patient be-
tween bilirubin/alkaline phosphatase levels and DU-PAN-2
antigen levels.
DISCUSSION
Agarose gel electrophoresis followed by immunoblotting
(Fig. 1) provides a means of assessing the molecular prop-
erties of the DU-PAN-2 antigen, the nature of the antigenic
determinant, and a method for determining the relationship
of DU-PAN-2 to other tumor-associated antigens with simi-
lar properties. The highly glycosylated nature of DU-PAN-2
molecules and their behavior on gels and density gradients
allows for their separation from many proteins and glycopro-
teins. More detailed studies on the molecular properties of
the DU-PAN-2 antigen will be reported separately. How-
ever, we did want to provide the reader of this report with
some visual data on the DU-PAN-2 antigen.
The competition RIA, as described in this report, appears
to be a rapid and sensitive assay for fluids containing mol-
ecules with the DU-PAN-2 epitope. The quantitation of DU-
PAN-2 antigen in terms of protein concentration is not jus-
tified because our most purified antigen preparations to date
had little protein and the epitope is carbohydrate. When
sufficient quantities of highly purified DU-PAN-2 antigen are
available we will be able to determine the weight of a stand-
ard antigen and express the results in weight units. For the
present purposes, however, quantitation of antigen concen-
tration by comparison to a standard reference has been
shown to be reliable and useful. We were initially concerned
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inhibition in the competition RIA. Although the reason for
this inhibition is still unknown, there are striking quantitative
differences in the levels of inhibition by normal donor sera
and those from pancreatic cancer patients. This difference
became apparent when the concentration of DU-PAN-2 an-
tigen was expressed in arbitrary units.
We were unable to adapt the DU-PAN-2 monoclonal anti-
body to a radioimmunometric type assay because this IgM
antibody lost much of its ability to bind antigen when cou-
pled to an insoluble matrix. "Second generation" murine
monoclonal antibodies and polyclonal rabbit antibodies to
purified DU-PAN-2 antigen preparations could result in pro-
duction of IgG antibodies or antibodies with greater binding
affinities to this antigen.
The detection of soluble tumor antigen in ascites and cyst
fluids may offer an approach to diagnosis of carcinoma
independent of cytologic examination. The number of pa-
tients with ascites or cyst fluid samples tested in this report
for DU-PAN-2 antigen is small, but impressive differences
were noted between the antigen activity in ascites from
patients with chronic renal failure or nonepithelial tumors
and ascites due to pancreatic carcinoma (Table 1). There
were also quantitative differences between the ascitic fluids
from pancreatic tumor patients and some of those from
patients with other solid tumors. This suggests that assay of
DU-PAN-2 antigen in ascitic fluids of patients with adeno-
carcinoma may help in determining the primary site of a
tumor. We were also able to detect high levels of antigen in
pancreatic duct fluids (Table 1). Consequently, it is possible
to evaluate DU-PAN-2 antigen levels in pancreatic secretion
samples taken from a variety of patients during endoscopic
cannulation of the pancreatic duct. Since many pancreatic
adenocarcinomas are located in the head of the pancreas and
often obstruct the pancreatic duct, these secretions may be a
good source of material for assays designed to facilitate early
detection of a primary tumor. The cyst fluid from the patient
with mucinous cystadenocarcinoma ofthe pancreas and some
of the ascites from pancreatic cancer patients also have
provided enriched sources of antigen for purification and
characterization studies.
It is the detection of DU-PAN-2 antigen in serum, how-
ever, that is of the greatest potential diagnostic value. Sera
from 77% of patients with pancreatic adenocarcinoma, irre-
spective of therapy or disease status, had increased levels
(>300 units/ml) of DU-PAN-2 antigen. Another antigen (CA
19-9), detected by a monoclonal antibody in a radioim-
munometric assay, has also been reported to be increased in
serum from patients with pancreatic adenocarcinoma (9, 10).
This antigen was shown to be a sialylated lacto-N-fucopen-
tose II epitope that on cell lines and tumor cells is associated
with a monosialoganglioside. In serum this antigen occurs as
a mucin (9, 10). Reagent exchanges, specificity studies, and
the inability of the 19-9 antibody to immunoblot the DU-
PAN-2 antigen indicate that the epitopes and molecules
detected by the 19-9 and DU-PAN-2 monoclonal antibodies
are different (unpublished data).
The presence of very high levels of antigen (10,000 to
100,000 units/ml) in sera from some pancreatic cancer pa-
tients may be a reflection of liver disease, since all of the
patients with these high levels had nonresectable liver metas-
tases. Thus, as with carcinoembryonic antigen, the serum
levels of the antigen may reflect not only its shedding or
release from a given tumor but also the ability of the patient
to catabolize the antigen (11). Elevation of serum DU-PAN-
2 antigen is not strictly a reflection of liver disease per se,
since some patients with colorectal carcinomas in this study
had impaired liver function with normal antigen levels, pre-
sumably because their tumors did not express DU-PAN-2
antigen (4).
This initial retrospective serum study does not allow us to
correlate DU-PAN-2 antigen levels with the status of disease
or liver function since it was not possible to determine the
exact tumor burden or have available the bilirubin levels on
many of the patients studied. This type of clinical correlation
can best be accomplished in a prospective study in which the
appropriate clinical and clinical laboratory data can be ob-
tained on the dates when body fluid samples are taken for
DU-PAN-2 antigen testing. However, the data from patient
B (Table 2) suggest that the assay may provide a sensitive
indicator for recurrence in a disease that has traditionally
been difficult to monitor. The test could be helpful for
identifying the origin of tumors with metastases, particularly
to the liver. We feel that the clinical applications of the
determination of DU-PAN-2 antigen in body fluids is en-
couraging but that a more comprehensive testing program is
warranted.
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